Homocysteine, cardiovascular inflammation, and myocardial remodeling

Area of Science:

• Cardiology
• Biochemistry
• Public Health

Background:

• Chronic heart failure presents a significant public health challenge, contributing to substantial morbidity and mortality.
• Elevated plasma homocysteine levels are increasingly recognized as a potent independent risk factor for heart failure, beyond atherosclerotic disease.
• Preclinical research indicates that hyperhomocysteinemia may promote adverse cardiac remodeling and failure through mechanisms involving inflammation and oxidative stress.

Purpose of the Study:

• To review current scientific data on the relationship between homocysteine and heart failure.
• To evaluate the pathogenic mechanisms linking hyperhomocysteinemia to cardiac dysfunction.
• To assess the clinical evidence supporting a causal role for hyperhomocysteinemia in cardiovascular disease.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of data on homocysteine levels and heart failure incidence.
• Examination of proposed pathogenic pathways including inflammation and oxidative stress.

Main Results:

• Preclinical studies suggest hyperhomocysteinemia contributes to heart failure via inflammation and oxidative stress.
• Clinical studies have not yet definitively established a causal link between hyperhomocysteinemia and cardiovascular disease.
• Homocysteine's role in heart failure pathogenesis requires further investigation.

Conclusions:

• While homocysteine is a risk factor for heart failure, its direct causative role in humans remains uncertain.
• Understanding the pathogenic mechanisms of hyperhomocysteinemia is crucial for developing targeted therapies.
• Further clinical research is warranted to clarify the etiological significance of homocysteine in heart failure.